title: Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: could it correlate with in vivo neuropathy?
abstract: Oxaliplatin is a platinum-organic drug with antineoplastic properties used for colorectal cancer. With respect to the other platinum derivates oxaliplatin induces only a mild hematological and gastrointestinal toxicity. Its limiting side effect is its neurotoxicity, which results in a sensory neuropathy. Repeated oxaliplatin treatment in the rat led to a neuropathic pain characterized by a significant oxidative damage throughout the nervous system. The natural antioxidants silibinin and α-tocopherol reduce redox alteration and prevent pain. Starting from the "oxidative hypothesis" as a molecular basis of chemotherapy-induced neurotoxicity, we decided to explore deep inside the mechanisms of oxaliplatin neurotoxicity and search for a cellular system useful for screening antioxidant compounds that can reduce oxaliplatin neurotoxicity. Focusing on various constituents of the central nervous system, we used the neuronal-derived cell line SH-SY5Y and primary cultures of rat cortical astrocytes. Oxaliplatin significantly increased superoxide anion production and induced lipid peroxidation (malonyldialdehyde levels) and protein (carbonylated proteins) and DNA oxidation (8-OH-dG levels). Silibinin and α-tocopherol (10µM) were able to reduce the oxidative damage in both cell types. These antioxidants fully protected astrocytes from the caspase 3 apoptotic signaling activation induced by oxaliplatin. The damage prevention effects of silibinin and α-tocopherol on nervous system-derived cells did not interfere with the oxaliplatin antineoplastic in vitro mechanism as evaluated on a human colon adenocarcinoma cell line (HT29). Moreover, neither silibinin nor α-tocopherol modified the oxaliplatin-induced apoptosis in HT29 cells, suggesting a different antiapoptotic profile in normal vs tumoral cells for these antioxidant compounds. In conclusion, because data obtained in in vitro cellular models parallel the in vivo study we propose cell models to investigate oxaliplatin neurotoxicity and to screen possible therapeutic adjuvant agents.
authors.affiliation: Department of Preclinical and Clinical Pharmacology, University of Florence, 50139 Florence, Italy. Electronic address: lorenzo.mannelli@unifi.it.
authors.forename: L
authors.initials: L
authors.lastname: Di Cesare Mannelli
authors.affiliation: Department of Preclinical and Clinical Pharmacology, University of Florence, 50139 Florence, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Zanardelli
authors.affiliation: Department of Preclinical and Clinical Pharmacology, University of Florence, 50139 Florence, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Failli
authors.affiliation: Department of Preclinical and Clinical Pharmacology, University of Florence, 50139 Florence, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Ghelardini
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D045744:Cell Line, Tumor; D006801:Humans; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D009944:Organoplatinum Compounds / Q000633:toxicity*; D000077150:Oxaliplatin; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D000077385:Silybin; D012838:Silymarin / Q000494:pharmacology; D014810:Vitamin E / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D012838:Silymarin; D000077150:Oxaliplatin; D014810:Vitamin E; D000077385:Silybin
keywords: Astrocyte; Disease modifying agent; Free radicals; HT-29; SH-SY5Y; Silibinin